- CA$39.86m
- CA$53.74m
- CA$10.03m
- 28
- 52
- 29
- 29
Annual cashflow statement for LSL Pharma, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2011 July 31st | 2012 July 31st | 2021 July 31st | 2022 July 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 15 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | CAS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.094 | -1.83 | -0.091 | -0.074 | -8.47 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.044 | 1.48 | — | — | 5.01 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.037 | 0.078 | 0.016 | 0.071 | -4.74 |
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -0.087 | -0.32 | -0.075 | -0.003 | -7.07 |
| Capital Expenditures | — | -0.528 | — | — | -1.02 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | 0.055 | — | — | — |
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | — | -0.473 | — | — | -1.02 |
| Financing Cash Flow Items | -0.121 | -0.119 | 0.065 | 0.004 | -2.83 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.079 | 0.874 | 0.065 | 0.004 | 8.1 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.007 | 0.081 | -0.01 | 0 | 0.008 |